Humacyte (HUMA) Cash from Operations (2020 - 2026)

Humacyte (HUMA) has reported Cash from Operations for 7 consecutive years, with -$22.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 16.34% year-over-year to -$22.1 million in Q2 2026; TTM through Jun 2026 was -$97.2 million, a 6.96% increase from a year earlier, with the FY2025 full-year figure at -$105.0 million, down 7.05% from the prior year.
• Cash from Operations was -$22.1 million for Q2 2026 at Humacyte, up from -$25.1 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$13.1 million in Q3 2023 and troughed at -$28.6 million in Q1 2025.
• A 5-year average of -$21.9 million and a median of -$22.3 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations soared 44.95% in 2022 and sank 75.45% in 2024, its largest moves.
• Over 5 years, Cash from Operations stood at -$18.9 million in 2022, then dropped by 0.4% to -$19.0 million in 2023, then tumbled by 39.84% to -$26.6 million in 2024, then rose by 1.7% to -$26.1 million in 2025, then advanced by 15.42% to -$22.1 million in 2026.
• The last three Cash from Operations figures came in at -$22.1 million (Q2 2026), -$25.1 million (Q1 2026), and -$26.1 million (Q4 2025), per Business Quant data.